View:
Download DOC
Download PDF
Download XLS

 

 
 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 27, 2017

 

FENNEC PHARMACEUTICALS INC.

 

(Exact name of registrant as specified in its charter)

 

001-32295
(Commission File Number)

     
British Columbia, Canada   20-0442384
(State or other jurisdiction of
incorporation) 		  (I.R.S. Employer Identification No.)

 

 

PO Box 13628, 68 TW Alexander Drive,
Research Triangle Park, NC		  

 

27709

(Address of principal executive offices)   (Zip Code)

 

 

Registrant’s telephone number, including area code: (919) 636-4530

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)    
         
☐   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)    
         
☐   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))    
         
☐   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))    
         

Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

On June 27, 2017, Fennec Pharmaceuticals Inc. (the “Company”) held an annual and special meeting of shareholders (the “Meeting”). The shareholders approved all proposals considered at the Meeting and approved all nominees of the Company for director, as follows:

 

1.                   The following five (5) nominees were elected to serve as directors, each to serve until the next annual meeting of shareholders of the Company or until their respective successor shall have been duly elected or duly approved:

 

Name of Nominee Votes For Votes Withheld Broker Non-Votes
Dr. Khalid Islam 9,243,659 2,562 1,326,909
Adrian Haigh 9,243,660 2,561 1,326,909
Chris A. Rallis 9,243,017 3,204 1,326,909
Marco Brughera 9,243,813 2,408 1,326,909
Rostislav Raykov 9,243,761 2,460 1,326,909

 

2.                   The resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration was approved based on the following vote:

 

Votes For 10,291,097
Votes Withheld 282,033
Abstentions 0
Broker Non-Votes 0

 

3.                   The ordinary resolution to approve the Shareholder Rights Plan Agreement was approved based on the following vote:

 

Votes For 9,244,726
Votes Against 1,495
Abstentions 0
Broker Non-Votes 1,326,909

 

4.                   The resolution to vote on the advisory vote on executive compensation was approved based on the following vote:

 

Votes For 9,242,927
Votes Against 3,294
Abstentions 0
Broker Non-Votes 1,326,909

 

 

 

 

  

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date June 29, 2017 By:

FENNEC PHARMACEUTICALS INC.

 

/s/ Rostislav Raykov

    Rostislav Raykov
Chief Executive Officer